Pacira BioSciences (PCRX) Revenue (2010 - 2026)

Pacira BioSciences' Revenue history runs 17 years deep, the most recent figure standing at $177.4 million for Q1 2026.

• In Q1 2026, Revenue rose 5.0% year-over-year to $177.4 million; the TTM figure through Mar 2026 stood at $734.9 million (up 4.57% YoY), while the FY2025 annual figure was $726.4 million, up 3.63% from the prior year.
• Revenue was $177.4 million for Q1 2026 at Pacira BioSciences, down from $196.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $196.9 million in Q4 2025 to a low of -$479.6 million in Q4 2022.
• Historically, Revenue has averaged $135.0 million across 5 years, with a median of $169.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Revenue plunged 401.27% in 2022, then jumped 137.79% in 2023.
• A 5-year view of Revenue shows it stood at -$479.6 million in 2022, then surged by 137.79% to $181.2 million in 2023, then rose by 3.32% to $187.3 million in 2024, then rose by 5.14% to $196.9 million in 2025, then declined by 9.9% to $177.4 million in 2026.
• The last three Revenue figures came in at $177.4 million (Q1 2026), $196.9 million (Q4 2025), and $179.5 million (Q3 2025), per Business Quant data.